Effect of Goserlin Acetate and Oxidative Stress in Iraqi Women with Recurrence of Endometriosis

Tamara Sami Naji1*, Salwa H. N. Al- Rubaei1,2 and Kisma M. Turki3
1PhD student at Department of Chemistry, College of Science, Al-Mustansiriya University, Baghdad, Iraq.
2Professor in Biochemistry, Department of Chemistry, College of Science, Al-Mustansiriya University, Baghdad, Iraq.
3Professor in Biochemistry, College of Medicine, Baghdad University, Baghdad, Iraq.

Abstract: Although surgery is currently the treatment of choice for managing endometriosis, recurrence poses a formidable challenge. Goserlinacetate is one of the most widely used medical therapies of endometriosis to induce ovarian suppression. The aim of this study was to evaluate the effect of goserlin acetate treatment on the hormonal changes (Luteinizing Hormone (LH), Follicle Stimulating Hormones (FSH), Testosterone (Test) and Estradiol (E2)), antioxidant status (A, E, β-carotene and C vitamins, Coenzyme Q10 (CoQ10), uric acid (UA) and oxidative stress (MDA) in goserlin-treated patients with endometriosis. Ninety women were participated in this study. Sixty women patients with endometriosis were undergoing laparoscopy and treated with goserlin acetate included as patients group (G1), age range was between 25-46 years. Thirty healthy women were selected as the control group (G2) age range was between 23-45 years. Results revealed that there is the highly significant difference between G1 and G2 groups in serum E2 levels. The results showed a significant higher (p<0.05) BMI, WH and LH/FSH and lower level of vitamin A in recurrent endometriosis in comparison with control group. Correlations studies indicated a significant correlation between testosterone, estradiol and MDA levels and antioxidant status of patients with endometriosis after the period of treatment. The relationship between the variables that increase in the Test. levels at the same time E2 levels displayed highly significant depletion in G1 patients compared with G2. The effect of goserlin acetate by increasing the levels of oxidative stress and decreasing levels of antioxidant status. It is considered one of the most side effects of this treatment and prefers to choose other types of hormonal treatment to get a better result.

Keyword: Recurrence endometriosis, goserlin acetate, oxidative stress and antioxidant.

I. Introduction

Endometriosis is a benign, estrogen-dependent, chronic gynecological disorder characterized by the presence of endometrial tissue outside the uterus. Lesions are usually located on dependent surfaces in the pelvis and most often affect the ovaries and cul-de-sac. They can also be found in other areas such as the abdominal viscera, the lungs, and the urinary tract. Endometriosis affects (6-10%) of women of reproductive age and is known to be associated with pelvic pain and infertility [1]. Endometriosis can be a recurrent disease, both after cessation of medical suppressive treatment and after surgical treatment. Recurrences of endometriosis after surgery can be explained by incomplete surgery, persistence and growth of microscopic endometriosis, the development of new lesions, or a combination of these factors. However, it is not known whether temporary and repeated exposure to high E2 levels during controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF) contributes to the recurrence of endometriosis [2]. Medical treatment of endometriosis typically involves hormonal manipulation of the menstrual cycle to create an amenorrheic state, thus producing an environment unfavorable to endometrial tissue. Danazol, progesterational drugs, gestrinone, oral contraceptives, and gonadotropin-releasing hormone (GnRH) agonists (GnRHa) are conventionally used medical agents. In addition, experimental medications, such as aromatase inhibitors, GnRH antagonists, pentoxifylline, tumor necrosis factor-α inhibitors, angiogenesis inhibitors, and matrix metalloproteinase inhibitors, hold the potential for greater efficacy and flexibility with fewer side effects[3]. GnRHa are one of the most widely used medical therapies for endometriosis. These agents induce medical menopause by down-regulating hypothalamic-pituitary GnRH receptors, thus causing decreased gonadotropin secretion, suppression of ovulation and reduced serum estrogen levels. Several GnRHa used for the treatment of endometriosis include nafarelin, buserelin, histrelin, triptorelin, leuprolide and goserlin acetate[4]. Goserelin acetate (trade name Zoladex) is a luteinizing hormone releasing hormone (LHHRH) agonist ((LHRHa)). It is a synthetic analog of LHRH. LHRH initially stimulate the release of LH, resulting in a transient elevation in serum estradiol in women. However, chronic administration can cause down-regulation of the LHRH receptors, thus inhibiting the secretion of LH and ultimately the sex hormones (androgen, estradiol). LHRHa reduce the ovarian secretion of estradiol and progesterone in women, leading to inhibition of
Effect of Goserlin Acetate and Oxidative Stress in Iraqi Women with Recurrence of Endometriosis

Estrogen-dependent cancers. Serum estradiol level is suppressed in women around 4 weeks after initiation of treatment. LH-RHAs are 50-100 times more potent than LH-RH. In addition, they have a longer duration of action due to increased receptor affinity and greater biological stability [5]. Estrogens have been shown to have in vitro antioxidant effects on membrane phospholipid peroxidation [6]. The antioxidant activity of estrogens is associated with the phenol structure of estradiol and its metabolites [7]. Oxidative stress (OS) substances may have a contributory role in the pathogenesis of endometriosis through the activation of macrophages. These activated macrophages can aggravate oxidative stress conditions by the production of lipid peroxides and other by-products from reaction between apolipoproteins and peroxides [8]. Vivian et al showed that production of reactive oxygen species (ROS) by peritoneal fluid mononuclear cells was increased in endometriosis [9]. Oxidative damage occurs as a result of deficient antioxidant defensive mechanisms due to the effect of endogenous and exogenous factors. The aim of this study was to investigate the effect of goserlin acetate treatment on the hormonal changes, antioxidant status and oxidative stress (MDA) in goserlin acetate-treated patients with endometriosis and attempted to find the correlation between all these parameters with lipid peroxidation, given by MDA level’s determination.

II. Materials and Methods

All chemical and reagents of analytical grade were purchased from Fluka unless indicated otherwise.

2.1 Subjects

Ninety women were participated in this study. Sixty women patients with endometriosis were undergoing laparoscopy and treated with goserlin acetate included as patients group (G1), age range was between 25-46 years. The women patients were treated in Baghdad Teaching Hospital-Medical City and Kamal Al-Samarray Hospital, Baghdad, Iraq from January to July 2015. Thirty healthy women were selected as the control group (G2) age range was between 23-45 years. Thirty patients of women excluded, who were smoking and suffering from chronic or acute diseases such as hypertension, diabetes mellitus, diseases of the liver and kidney.

2.2 Anthropometric Measurements

Body mass index (BMI) was calculated as weight (kg) divided by the height² (m²). Patients were taken as obese if their body mass index was 29.9 [10]. Waist:hip ratio (WHR) was calculated by dividing waist by hip measurements [11].

2.3 Samples Analysis

2.3.1 Specimen collection

Fasting blood samples (10 mL) were collected and placed into containing tubes during 2-5 days of the menstrual cycle. After centrifugation at 1500×g for 10 min. the sera were removed and retained for assay of the level of vitamin C and all the parameters, respectively. Serum samples were stored at -80°C until analysis.

2.3.2 Laboratory assessments

Serum concentration of (LH, FSH, Test, and E2) were measured by mini-VIDIS assay using kit supplied by Bio Merieux Sa-France. UA was measured with an enzymatic colorimetric assay using a kit supplied by Cromatest-Spanish. CoQ₁₀ was measured with a competitive inhibition enzyme immunoassay technique using a kit supplied by HCUSABIO-China. The vitamins (A, E & β-carotene) were determined by a reverse-phase HPLC technique consisting of a Shimadzu-Japan binary solvent metering pump, a Rhodyne7125 injector with a 150µL sample loop, column (25cm×4.6mm inner diameter), 5μm particle size, injection volume 50 µL and 10AV UV–Visible detector operating at λ max 280 nm and 450 nm [12-13]. Vitamin C determination is based on the oxidation of ascorbic acid in serum by Cu²⁺ to form dehydroascorbic acid that react with the acidic 2,4-dinitrophenyl hydrazine to form a red bis-hydrazone which is measured as (A 520 nm) [14]. Malondialdehyde formed from the breakdown of poly unsaturated fatty acids serves as a convenient index of peroxidation reaction. The thiobarbituric acid method of [15], was used to measure MDA.

2.4 Statistical analysis

All data were expressed as mean ± standard deviation (mean ± SD). Statistical analysis was performed using LSD, considering p < 0.05 as the lowest limit of significance. Statistical analysis was performed using a software program (SPSS 13 for Windows, USA). One-way analysis of variance (ANOVA) was used to compare means with least significant difference (LSD).

III. Results

As Table 1 recurrence of endometriosis was visualized in 60 cases included 4-6 months (70.0%) and 1-2 years (30.0%) period of illness, among the cases, (78.3%) were reported to have infertile status and (21.6%) had healthy state, cases were more likely to have ovarian stimulation drug (63.3%). Table 2 indicates the
The majority of mean values (BMI, W/H ratio, LH, FSH, LH/FSH ratio, Test., (UA and MDA as table 3)) were estimated at the study of endometriotic patients with goserelin acetate treatment group (G1) (28.03±6.5Kg/m², 0.87±0.17, 5.64±2.09mIU/mL, 6.79±3.11 mIU/mL, 0.83±0.45, 0.52±0.26mg/mL, 378.71±27.78 μmol/L and 1.97±0.52 μmol/L) respectively, while the lowest values estimate were recorded in normal interval with the control group (G2), (25.30±2.66Kg/m², 0.79±0.08, 4.96±2.40mIU/mL, 6.60±1.84mIU/mL, 0.75±0.19, 0.27±0.11ng/mL, 232.43±30.70μmol/L and 0.65±0.12 μmol/L) respectively. Table 3 displayed the lowest mean values of antioxidant vitamins (A, E, β-carotene, C and CoQ₁₀) and (E₂ as table 2) levels were estimated in G1, (0.03±0.01mg/dL, 0.86±0.26 mg/dL, 0.09±0.01mg/dL, 1.12±0.41mg/dL, 33.04±9.83ng/mL and 33.94±5.82pg/mL) respectively, while the majority values estimate were in the G2 (0.04±0.0 mg/dL, 0.98±0.29mg/dL, 0.17±0.05mg/dL, 1.68±0.20mg/dL and 42.31±3.64ng/mL and 51.18±14.44pg/mL) respectively. The results from this study revealed that (Test., UA and MDA) levels were highly significant increased (p<0.01), while a (BMI, W/H and LH/FSH) levels were significant increased (p<0.05). Vitamins (β-carotene, C and CoQ₁₀) and E₂ showed a highly significant decreased (p<0.001). However, a significant decreased (p<0.05) was noticed in vitamin A level, LH and FSH levels were non significant increased (p>0.05), whereas an antioxidant vitamins decreased (p<0.05) of vitamin E level in G1 compared with G2. Table 4 shows the correlation between oxidative stress index (represented by MDA level) and concentration of hormones, antioxidant vitamins and uric acid in recurrent endometriotic patients. There was a negative correlation between the levels of LH/FSH ratio, E₂, Vitamins A, E, CoQ₁₀ and UA. Whereas positive correlation was observed between LH, FSH, β-carotene, vitamin C and Test. with increased in MDA levels.

Table 1. Characteristics of the recurrent endometriotic patients in this study.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Duration of disease</th>
<th>Distribution among total subjects (n=60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>(4-6) months</td>
<td>42(70.0%)</td>
</tr>
<tr>
<td>Duration</td>
<td>(1-2) years</td>
<td>18(30.0%)</td>
</tr>
<tr>
<td>Marital status</td>
<td>Married</td>
<td>1(1.6%)</td>
</tr>
<tr>
<td>Marital status</td>
<td>Unmarried</td>
<td>59(98.3%)</td>
</tr>
<tr>
<td>Case of reproduction</td>
<td>Infertile women</td>
<td>47(78.3%)</td>
</tr>
<tr>
<td>Case of reproduction</td>
<td>Healthy women</td>
<td>13(21.6%)</td>
</tr>
<tr>
<td>Ovarian stimulation drug</td>
<td>Yes (Puregon+Tamoxifen)</td>
<td>38(63.3%)</td>
</tr>
<tr>
<td>Ovarian stimulation drug</td>
<td>No</td>
<td>22(36.6%)</td>
</tr>
</tbody>
</table>

Table 2. The morphological and clinical characteristics measurements in sera of the studied groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>G1 (patients) (N=60) Mean ± SD</th>
<th>G2 (control) (N=30) Mean ± SD</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>32.86±6.17</td>
<td>31.96±5.42</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>28.03±6.55</td>
<td>25.30±2.66</td>
<td>0.013*</td>
</tr>
<tr>
<td>Waist/Hip ratio</td>
<td>0.87±0.17</td>
<td>0.79±0.08</td>
<td>0.015*</td>
</tr>
<tr>
<td>LH (mIU/mL)</td>
<td>5.64±2.09</td>
<td>6.79±3.11</td>
<td>NS</td>
</tr>
<tr>
<td>FSH (mIU/mL)</td>
<td>6.60±1.84</td>
<td>6.60±1.84</td>
<td>NS</td>
</tr>
<tr>
<td>LH/FSH</td>
<td>0.83±0.45</td>
<td>0.75±0.19</td>
<td>0.003*</td>
</tr>
<tr>
<td>Test. (ng/mL)</td>
<td>0.52±0.26</td>
<td>0.27±0.11</td>
<td>0.001**</td>
</tr>
<tr>
<td>CoQ₁₀ (ng/mL)</td>
<td>33.94±5.82</td>
<td>51.18±14.44</td>
<td>0.001**</td>
</tr>
</tbody>
</table>

*NS: non significant at p>0.05, *significant at p<0.05 and ** highly Significant at p≤0.01 level.

Table 3. Serum levels of antioxidant status and MDA in G1 and G2 groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>G1 (patients) (N=60) Mean ± SD</th>
<th>G2 (control) (N=30) Mean ± SD</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vit. A (mg/dL)</td>
<td>0.03±0.01</td>
<td>0.04±0.01</td>
<td>0.006*</td>
</tr>
<tr>
<td>Vit. E (mg/dL)</td>
<td>0.86±0.26</td>
<td>0.98±0.29</td>
<td>NS</td>
</tr>
<tr>
<td>β-carotene (mg/dL)</td>
<td>0.09±0.01</td>
<td>0.17±0.05</td>
<td>0.001**</td>
</tr>
<tr>
<td>Vit. C (mg/dL)</td>
<td>1.12±0.41</td>
<td>1.68±0.20</td>
<td>0.001**</td>
</tr>
<tr>
<td>CoQ₁₀ (ng/mL)</td>
<td>33.04±9.83</td>
<td>42.31±5.64</td>
<td>0.001**</td>
</tr>
<tr>
<td>UA (μmol/L)</td>
<td>378.71±27.78</td>
<td>232.43±30.70</td>
<td>0.001**</td>
</tr>
<tr>
<td>MDA (μmol/L)</td>
<td>1.97±0.57</td>
<td>0.65±0.12</td>
<td>0.001**</td>
</tr>
</tbody>
</table>

*NS: non significant at p>0.05, *significant at p<0.05 and ** highly Significant at p≤0.01 level.
Endometriosis is a common disease, defined as the presence of endometrial-like tissue outside the uterus, which induces a chronic, inflammatory reaction. While some women with endometriosis can experience painful symptoms and/or infertility, others have no symptoms at all. Susceptibility to endometriosis depends on a complex interaction of immunologic, genetic and hormonal factors [16]. Theoretically, the recurrent lesions might originate from either residual lesions or de novo cells coming through retrograde bleeding. For the former assumption, several studies demonstrate that the recurrence risk increases if the lesions are not completely removed at the initial surgery and they tend to arise on the same location [17]. Six months of GnRHa therapy immediately following surgery reduces the rate of symptom recurrence of endometriosis, and increases the length of time before symptoms recur. It is also more effective in managing endometriosis-related pain after surgery than using oral contraceptive in the same way [18].

In one study, women with endometrial hyperplasia received goserlin acetate and after this treatment, 82.8% showed a reversal of hyperplasia as assessed by clinical and histological examination. Furthermore, endometrial hyperplasia, can contribute to the discussion of the effect of androgens on endometrial growth and is more common among obese women and is associated with higher BMI and correlated with higher testosterone and lower estradiol. Goserelin acetate, a testosterone derivative, to reverse endometrial growth, but the potential occurrence of testosterone surges on repeat injection is a concern [20].

Hormone therapy is commonly utilized because endometrial tissue responds to hormone stimulation. Estrogen increases the risk of related diseases than the grade of obesity as determined by the BMI [21]. Reckless that greater waist to hip ratio is associated with risk of endometriosis. This finding supports the highly significant increase of W/H ratio in G1. Conventional medical treatment of endometriosis focuses on reducing estrogen stimulation, managing pain and preserving fertility. Hormone therapy is commonly utilized because endometrial tissue responds to hormone stimulation. Estrogen has been shown to increase aberrantendometrial lesions, while progesterone and androgens may decrease implant size [22]. Studies of the effects of testosterone derivative used in the treatment of endometriosis, menorrhagia, and endometrial hyperplasia, can contribute to the discussion of the effect of androgens on endometrial growth.

In one study, women with endometrial hyperplasia received goserlin acetate and after this treatment, 82.8% showed a reversal of hyperplasia as assessed by clinical and histological examination. Furthermore, endometrial hyperplasia was detected in 65.8%, and amenorrhea in 90%. These findings support the biological capacity of goserlin acetate, a testosterone derivative, to reverse endometrial growth [23]. In the current study, it is found that an increased in Test levels in G2, due to the potential occurrence of testosterone surges on repeat injection of the goserelin acetate has also been investigated by [24]. Conversely, the highly significant decrease of estrogen in G2 compared with G1. Goserelinacetate is medicines that work by causing a temporary menopause. They are modified forms of GnRH that bind to receptors in the pituitary but have a longer half-life than native GnRH and thereby in down-regulation of the pituitary-ovarian axis and hyperestrogenism. The treatment causes the ovaries to stop producing estrogen, which causes the endometriosis implants to shrink [25].

Studies of the effects of testosterone derivative used in the treatment of endometriosis, menorrhagia, and endometrial hyperplasia, can contribute to the discussion of the effect of androgens on endometrial growth.

In one study, women with endometrial hyperplasia received goserlin acetate and after this treatment, 82.8% showed a reversal of hyperplasia as assessed by clinical and histological examination. Furthermore, endometrial hyperplasia was detected in 65.8%, and amenorrhea in 90%. These findings support the biological capacity of goserlin acetate, a testosterone derivative, to reverse endometrial growth [23]. In the current study, it is found that an increased in Test levels in G2, due to the potential occurrence of testosterone surges on repeat injection of the goserelin acetate has also been investigated by [24]. Conversely, the highly significant decrease of estrogen in G2 compared with G1. Goserelinacetate is medicines that work by causing a temporary menopause. They are modified forms of GnRH that bind to receptors in the pituitary but have a longer half-life than native GnRH and thereby in down-regulation of the pituitary-ovarian axis and hyperestrogenism. The treatment causes the ovaries to stop producing estrogen, which causes the endometriosis implants to shrink [25]. Murphy et al, who found that women with endometriosis had significantly lower levels of antioxidants than women without endometriosis, and significantly higher levels of lipid peroxides [27]. A study by [28] reported that serum CoQ10 levels were higher among postmenopausal than among premenopausal women, suggesting that circulating steroid hormone or gonadotropin concentrations may influence plasma levels of CoQ10. For this reason, it is possible that we propose in this study that the effect of goserelin acetate was evident in the endometriotic patients that migratory rise Test hormone and lower level of estradiol that affects the level of CoQ10. Indeed, uric acid is the most abundant aqueous antioxidant, accounting for up to 60% of plasma antioxidative capacity. The antioxidative effect of uric acid is evidenced by its ability to directly scavenge free radicals.
radicals or to form stable complexes with transition-metal ions, such as iron, thereby preventing ascorbate oxidation and lipid peroxidation [29]. Jackson et al found that there was a positive association between oxidative stress and endometriosis [30]. In the current study, it is found the correlation between MDA and different variables measured in goserlin acetate-treated patients. These correlations were represented by a linear regression where the slope represents the direct effect of MDA on each variables level in patients, while the intercept represents the accumulative effect of other factors. A positive significant correlation between MDA and testosterone hormone in recurrent endometriotic patients. A negative correlation between E2 and MDA. Our findings suggest that ovarian E2 production may play an important antioxidant role, an inverse correlation between E2 and lipid peroxide production with aging have been reported [31]. Whereas anagenteive correlation between MDA level and vitamins (A, E, UA and CoQ10), suggesting a deficiency in these vitamins or its consumption as an antioxidant secondary to the excessive production of free radicals.

V. Conclusion

From all the aforementioned observations it can be concluded that there is a significant and very effective role of goserlin acetate in alteration of the hormones changes and antioxidants status of women patients with endometriosis after the period of treatment. The results of this study showed the relationship between the variables that increase in the Test levels at the same time E2 levels displayed highly significant depletion in G1 patients compared with G2. In addition, the result of this study describes the effect of goserlin acetate by increasing the levels of oxidative stress and the low levels of antioxidant status. It is considered one of the most side effects of this treatment and prefers to choose other types of hormonal treatment to get a better result.

References

Effect of Goserlin Acetate and Oxidative Stress in Iraqi Women with Recurrence of Endometriosis


